To view this email as a web page, click here.
 
GENITOURINARY CANCERS
 
PET use in prostate Ca widens, but questions remain
In this interview, Mark Frydenberg, MD, discusses the evolution of PET scanning, its clinical indications, its advantages and drawbacks, and key questions that remain about its use.
Read the interview
 
Bladder Ca biomarkers and BCG: New knowledge of the urinary microbiome
“Relationships between microbes and symptoms have led to considerable excitement about the potential for previously uncharacterized relationships between the urinary microbiome and other urologic diseases, including bladder cancer,” write Ryan A. Dornbier, MD, Peter Bajic, MD, and Gopal N. Gupta, MD.
Learn more
 
SURVEY
 
Is DRE still a relevant tool in the management of prostate cancer?
ADVERTISEMENT
Reviewing long-term survival with immunotherapy for mCRPC
The introduction of an autologous cellular immunotherapy began a paradigm shift in the treatment of metastatic castrate-resistant prostate cancer (mCRPC). That was in 2010. This Urology Times Partner Perspective offers practical considerations for the use of immunotherapy in mCRPC. Read it now.
 
MORE FROM UROLOGY TIMES
 
Neoadjuvant chemohormonal therapy efficacious for high-risk PCa
PSA adjustments are required in men taking 5-ARIs
JOB OPPORTUNITIES
 
NY-WNY Urology Associates
VT-University of Vermont
VT-University of Vermont
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.